NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC
-Two human phase II clinical trials to be conducted in 2021
-One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis
-The second trial will focus on ETEC infections
finance.yahoo.com/news/us-dod-naval-medical-research-100010355.html
-Two human phase II clinical trials to be conducted in 2021
-One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis
-The second trial will focus on ETEC infections
finance.yahoo.com/news/us-dod-naval-medical-research-100010355.html
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.